Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | PI4KA | P42356 | 4/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9884055 | 0.82 | CYP2C19 (0.67) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18587087 | 0.79 | NPC1 (0.61) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL17009420 | 0.78 | CYP2C19 (0.54) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL27920376 | 0.77 | NPC1 (0.69) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4572213 | 0.76 | CYP2C19 (0.74) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL31569297 | 0.76 | CYP2C19 (0.74) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29665002 | 0.76 | NPC1 (0.64) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL18587962 | 0.76 | NPC1 (0.64) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL675830 | 0.75 | PI4KA (0.92) | CYP2C19PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL115599 | 0.75 | CYP2C19 (0.68) | CYP2C19PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | MITOKININ, INC. (US) | 2021-04-15 | — | — | US | disclosed |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10167286-B2 | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | MITOKININ, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | Mitokinin, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2015123365-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | MITOKININ LLC (US) | 2015-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107910-A1 | Compositions and Methods of Using the Same for Treatment of Neurodegenerative and Mitochondrial Disease | NLN, NME4, COQ8A | CYP2C19 1436/4885PI4KA 3350/4885PI4K2B 3271/4885 |
| US-20190194207-A1 | COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, PDF | CYP2C19 4319/4885PI4KA 4199/4885PI4K2B 3857/4885 |
| US-10167286-B2 | Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | CYP2C19 1290/4885PI4KA 3084/4885PI4K2B 3024/4885 |
| US-10851109-B2 | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | NLN, NME4, COQ8A | CYP2C19 1436/4885PI4KA 3350/4885PI4K2B 3271/4885 |
| US-20170190704-A1 | COMPOSITIONS AND METHODS USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE | NLN, HAGH, MT-ND2 | CYP2C19 4071/4885PI4KA 3867/4885PI4K2B 3099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.